<DOC>
	<DOCNO>NCT00088673</DOCNO>
	<brief_summary>The purpose Phase III study evaluate efficacy safety 3APS compare placebo ( inactive substance pill ) patient mild moderate Alzheimer ’ disease .</brief_summary>
	<brief_title>Evaluation 3APS Patients With Mild Moderate Alzheimer ’ Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Tramiprosate</mesh_term>
	<criteria>Patients may include study meet follow criterion : Male Female ( age 50 year old ) : Female must nonchildbearing potential ( i.e . surgically sterilize least 2 year postmenopausal ) . Diagnosis probable Alzheimer ’ disease base National Institute Neurological Communicative Disorders Stroke/Alzheimer ’ Disease Related Disorders Association ( NINCDSADRDA criterion ) . Severity dementia mild moderate degree assess Mini Mental State Examination ( MMSE ) perform screen visit . Patient must live community reliable caregiver . Participant living assist living facility may include study medication intake supervise participant reliable caregiver . Potential participant must treat conventional Alzheimer ’ disease therapy must stable dose least 4 month prior screen visit entire study period . Fluency English , French Spanish ( oral write ) . Signed informed consent potential participant legal representative caregiver . Patients eligible participate study meet follow criterion : Potential participant cause dementia . Life expectancy le 2 year . Potential participant clinically significant and/or uncontrolled condition significant medical disease . Use investigational drug within 30 day prior screen visit entire study . Previous use 3APS . Patient recruitment do participate center .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Alzheimer Disease</keyword>
</DOC>